The purpose of this resource grant is to function as a core to maintain and create dogs with hemophilia A, hemophilia B, and von Willebrand disease (WVD) for collaborations with other investigators. Our objectives are: 1) To maintain a breeding colony of well-characterized dogs with genetically-determined bleeding disorders at the Francis Owen Blood Research Laboratory (FOBRL), University of North Carolina, Chapel Hill;2) To produce purpose-bred, affordable research animals with these bleeding disorders in a cost effective manner;and 3) To provide specialized support services for research projects using these dogs including canine blood banking and coagulation analyses. These dogs, identified by Dr. Kenneth M. Brinkhous, model human hemophilias and VWD and have been maintained for >50 years at UNC largely through NIH support. Research using the FOBRL dogs has more than doubled during the past 20 years and has led to discoveries that have revolutionized the treatment of inherited and acquired bleeding and thrombotic disorders. Many therapeutic agents were developed and tested in these dogs and successfully translated into clinical therapeutics. Thus many advisory boards recommend these dogs as essential for preclinical testing of new treatments for the hemophilias, VWD, and hemorrhage. Major accomplishments during the past 5 years include 24 peer-reviewed publications, over 36 abstract presentations, and obtaining funding separate from but leveraged by this grant that built new, dedicated hemophilia and VWD dog housing. A highly trained staff at the FOBRL has several years of experience in maintaining these special dogs with a dedicated canine blood bank, developing canine coagulation assays, conducting investigations, and collaborating successfully with investigators worldwide. Current research addresses several unmet national needs that include testing new treatments for bleeding, developing a new strain of hemophilia A dogs with inhibitors, and determining the acute and chronic sequelae of gene therapy on genetic diseases. This grant is the only support for maintenance of this colony. Without this grant, new research using these valuable bleeder dogs would be very difficult and expensive to initiate and the survival of this colony would be jeopardized. The cost of establishing a colony at each investigator's institution is prohibitive. This Resource Grant is essential to ensure the survival of the colony in an established, successful environment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Resource-Related Research Projects (R24)
Project #
5R24HL063098-14
Application #
8286377
Study Section
Special Emphasis Panel (ZHL1-CSR-N (M1))
Program Officer
Link, Rebecca P
Project Start
2008-09-15
Project End
2013-07-31
Budget Start
2012-07-01
Budget End
2013-07-31
Support Year
14
Fiscal Year
2012
Total Cost
$722,913
Indirect Cost
$232,869
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Sauna, Zuben E; Lozier, Jay N; Kasper, Carol K et al. (2015) The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics. Blood 125:223-8
Sherman, Alexandra; Schlachterman, Alexander; Cooper, Mario et al. (2014) Portal vein delivery of viral vectors for gene therapy for hemophilia. Methods Mol Biol 1114:413-26
Pope, Ava G; Wu, Gongting; McWhorter, Frances Y et al. (2013) Contrast-enhanced imaging of SPIO-labeled platelets using magnetomotive ultrasound. Phys Med Biol 58:7277-90
Lozier, Jay N; Nichols, Timothy C (2013) Animal models of hemophilia and related bleeding disorders. Semin Hematol 50:175-84
Sabatino, Denise E; Nichols, Timothy C; Merricks, Elizabeth et al. (2012) Animal models of hemophilia. Prog Mol Biol Transl Sci 105:151-209
Nichols, T C; Franck, H W G; Franck, C T et al. (2012) Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs. J Thromb Haemost 10:474-6
Scola, Mallory R; Baggesen, Leslie M; Nichols, Tim C et al. (2012) A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach. Thromb Res 129 Suppl 2:S57-61
Sabatino, Denise E; Lange, Amy M; Altynova, Ekaterina S et al. (2011) Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther 19:442-9
Knudsen, T; Kristensen, A T; Nichols, T C et al. (2011) Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog. Haemophilia 17:962-70
Knudsen, Tom; Kjalke, Marianne; Tranholm, Mikael et al. (2011) Development of a flow cytometric assay for detection of coated platelets in dogs and evaluation of binding of coated platelets to recombinant human coagulation factor VIIa. Am J Vet Res 72:1007-14

Showing the most recent 10 out of 26 publications